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OBJECTIVE—Weak major histocompatibility complex (MHC)
binding of self-peptides has been proposed as a mechanism that
may contribute to autoimmunity by allowing for escape of
autoreactive T-cells from the thymus. We examined the relation-
ship between the MHC-binding characteristics of a -cell antigen
epitope and T-cell autoreactivity in a model of autoimmune
diabetes.
RESEARCH DESIGN AND METHODS—The binding of a
proinsulin epitope, proinsulin-1(47–64) (PI-1[47–64]), to the
MHC class II molecules I-A
g7 and I-A
k was measured using
puriﬁed class II molecules. T-cell reactivity to the proinsulin
epitope was examined in I-A
g7 and I-A
k mice.
RESULTS—C-peptide epitopes bound very weakly to I-A
g7
molecules. However, C-peptide–reactive T-cells were induced
after immunization in I-A
g7–bearing mice (NOD and B6.g7) but
not in I-A
k–bearing mice (B10.BR and NOD.h4). T-cells reactive
with the PI-1(47–64) peptide were found spontaneously in the
peripancreatic lymph nodes of pre-diabetic NOD mice. These
T-cells were activated by freshly isolated -cells in the presence
of antigen-presenting cells and caused diabetes when transferred
into NOD.scid mice.
CONCLUSIONS—These data demonstrate an inverse relation-
ship between self-peptide–MHC binding and T-cell autoreactivity
for the PI-1(47–64) epitope in autoimmune diabetes. Diabetes
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D
efective negative selection caused by weak
interactions between self-peptides and major
histocompatibility complex (MHC) molecules
has been proposed as a mechanism that may
contribute to autoimmunity. We have been interested in
examining the relationship between peptide-MHC interac-
tions and T-cell autoreactivity for disease-relevant anti-
gens in autoimmune diabetes. In the case of the nonobese
diabetic (NOD) mouse, the class II MHC molecule, I-A
g7,
has been shown to be a weak peptide binder (1). While
examining the CD4 T-cell response to peptides derived
from the insulin -chain in the NOD mouse, we were
struck by its low binding afﬁnity to the I-A
g7 class II MHC
molecule (2). Many of the spontaneous T-cells that were
identiﬁed reacted to a segment previously identiﬁed as a
focus for spontaneous T-cell reactivity (3–6). Such a
peptide apparently bound in two registers to I-A
g7, but
binding was in the low micromolar range and showed a
fast dissociation rate. Many of the amino acids in the
peptide affected both binding and T-cell recognition, im-
plying a very loose peptide-MHC complex (2).
The relationship of low afﬁnity of a peptide to an MHC
molecule and autoimmune reactivity has also been noted
in the encephalitogenic peptide from myelin basic protein
(7,8). This has led to the speculation that low-afﬁnity
peptides may not be conducive to the normal mechanisms
in the thymus that control autoreactivity. A study by
McNeil and Evavold noted that peptides with fast dissoci-
ation rates and poor binding to MHC molecules were
ineffective at deleting thymocytes even though the same
ligands were capable of eliciting proliferation of mature
T-cells in the periphery (9). Similarly, in a tumor model
system,low-afﬁnityepitopeswereshowntoactivatetumor-
speciﬁc cytotoxic T-lymphocytes and could confer anti-
tumor immunity on immunization (10). Lastly, a study by
Roep and colleagues (11) that measured in vitro binding
interactions of proinsulin epitopes to various HLA-DR
molecules noted that DR alleles associated with protection
from diabetes bound various proinsulin epitopes with a
higher afﬁnity when compared with DR molecules that
predispose to type 1 diabetes.
To further characterize the relationship between pep-
tide-MHC binding strength and immune reactivity, we have
examined other regions of the proinsulin molecule tar-
geted by CD4 T-cells. The insulin molecule is derived from
the processing of the prohormone proinsulin and is se-
creted from the pancreatic -cell with equimolar amounts
of the connecting peptide C-peptide (Table 1) (12). We
examined the proinsulin-1(47–64) (PI-1[47–64]) (SPG-
DLQTLALEVARQKRG) segment because reactivity to it
had been found in NOD mice (5,13). These data extend our
understanding of the role of proinsulin as an autoantigen
in type 1 diabetes and demonstrate an inverse relationship
between peptide-MHC afﬁnity and T-cell autoreactivity
against a deﬁned -cell antigen epitope.
RESEARCH DESIGN AND METHODS
NOD, NOD.scid, NOD.h4, B6.g7, and B10.BR mice were purchased from The
Jackson Laboratories (Bar Harbor, ME). All mice were housed and cared for
in accordance with the guidelines of the Washington University Committee for
the Humane Care of Laboratory Animals and with National Institutes of Health
guidelines on laboratory animal welfare.
Peptides. Synthetic peptides were purchased from Biosynthesis (Lewisville,
TX). All peptides were 95% pure, conﬁrmed by high-performance liquid
chromatography and mass spectrometry analysis.
Peripancreatic lymph node assays. Spleens, axillary and inguinal lymph
nodes, and peripancreatic lymph nodes (PPLNs) were isolated from 10- to
16-week-old male and female NOD mice and dispersed into single-cell
suspensions by passage through cell strainers. The splenocytes or lymph node
cells (3–5  10
4/well) were subsequently cultured with irradiated NOD
splenocytes (5  10
5/well) and 1–5 mol/l peptide for 7 days in round-bottom
96-well plates in a ﬁnal volume of 200 l. On day 7, the cultures were
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1852 DIABETES, VOL. 57, JULY 2008re-stimulated with fresh irradiated NOD splenocytes (5  10
5/well), 25
units/ml interleukin (IL)-2, and 1–5 mol/l peptide. T-cell–positive wells were
tested days 14–17 with antigen-presenting cells (APCs) and 10 mol/l peptide.
Only data from cells with 200 counts per minute were considered, the
stimulation index was calculated by dividing values for APCs plus peptide by
APCs alone. The data presented in Fig. 2A were pooled from seven indepen-
dent experiments. All tissue culturing was done in Dulbecco’s modiﬁed
Eagle’s medium (DMEM) supplemented with 10% FCS (DMEM 10% FCS).
Primary T-cell lines. The anti–C-peptide (ACP) primary T-cell lines were
generated by immunization of 8- to 10-week-old NOD mice with 10 nmol
PI-1(47–64) in complete Freund’s adjuvant (CFA). Immunized lymph nodes
were harvested at day 7 and cultured at 5  10
5 cells/well in DMEM with 10%
FCS and 1 mol/l peptide. On day 7, and at 7- to 10-day intervals thereafter, the
T-cells (1–2  10
3–4/w) were restimulated with fresh irradiated NOD spleno-
cytes (5  10
5 cells/well), IL-2 (25 units/ml), and peptide (1 mol/l). Hybrid-
omas were generated from these primary lines by fusion to the BW5147
--thymoma partner cell line following standard techniques (14).
T-cell assays. Primary T-cell proliferation assays were performed by incuba-
tion of T-cells (2  10
4/well) with irradiated NOD splenocytes (5  10
5/well)
in the presence of peptide or dispersed mouse -cells. Primary T-cell
proliferation assays were pulsed with thymidine (1 Ci/well) on day 2 and
harvested day 3. T-cell hybridoma assays were performed with NOD spleno-
cytes or the I-A
g7–expressing cell line, C3G7 (2.5  10
4/well), as APCs and
supernatants were collected at 24 h for IL-2 quantitation by cytotoxic
T-lymphocyte line assay. Fixation of the C3G7 cell line was performed by
incubation in 1% paraformaldehyde for 15 min followed by incubation in 0.2
mol/l DL-lysine for 10 min and then washing three times in DMEM 10% FCS.
Islet isolation. Islets of Langerhans were isolated from mice of various ages
and dispersed using standard techniques (15). The digestion of the pancreatic
tissue was performed with type XI collagenase (Sigma, St. Louis, MO) without
DNase.
Enzyme-linked immunosorbent spot-forming cell analysis. Mice were
immunized with 10 nmol PI-1(47–64) peptide in CFA and lymph nodes were
examined on day 7 by enzyme-linked immunosorbent spot-forming cell
(ELISPOT) analysis for IL-2
 cells. Lymph node cells (1  10
6/well) were
plated in triplicate on anti–IL-2 capture antibody–coated ﬁlter plates in the
presence of 10 mol/l antigen and developed 24 h later with anti–IL-2
detection antibodies (BD Biosciences, San Jose, CA). Plates were read by
C.T.L. Cellular Technology and analyzed with ImmunoSpot 3.2 software.
Peptide-binding assays. Soluble I-A
g7 or I-A
k was produced using the
recombinant baculovirus system as previously described (16). Peptide binding
assays were done under acidic (pH 5.5) conditions. Brieﬂy, 0.5–1 g I-A
g7 or
I-A
k/class II–associated invariant chain peptide was treated with 0.1 unit
thrombin to cleave both the zipper tails and peptide linker (Novagen, Madison,
WI) and simultaneously incubated with 0.125 pmol I
125-radiolabeled mimotope
reference peptide (GKKVATTVHAGYG) and increasing doses of unlabeled
peptides in 200 mmol/l Tris(2-carboxyethyl) phosphine hydrochloride, 20
mmol/l MES, and 150 mmol/l sodium chloride. Binding reactions were
incubated overnight at 25°C in 30-l volumes. Complexes were puriﬁed from
free peptide by gel ﬁltration Bio-spin columns (Bio-Rad). The percentage of
bound peptide was evaluated by gamma counting. Usually, 25–35% of input
peptide was bound, whereas 0.5% of peptides nonspeciﬁcally passed through
the Bio-spin columns. The half-maximal inhibitory concentration (IC50) value
is very close to the binding equilibrium constant. The IC50 values shown in
Table 2 are averages of three to ﬁve independent binding experiments.
Biological dissociation rates. The C3G7 APC line was incubated with
peptide (10 mol/l) for 2 h and washed. ACP T-cells (2  10
4/well) were added
to the APC-containing wells (2.5  10
4/well) cultures at time zero and at 4 and
8 h after washing. The supernatants were collected at 24 h, and IL-2 was
measured by cytotoxic T-lymphocyte line assay.
Adoptive T-cell transfer. Two of the three primary ACP T-cell lines were
expanded in vitro and transferred into 8- to 12-week-old NOD.scid recipients
by tail vein injection. Diabetes was deﬁned by the measurement of blood
sugars 250 mg/dl on two separate occasions. All recipients were followed for
30 weeks or up to disease onset.
RESULTS
The PI-1(47–64) peptide bound weakly to I-A
g7. Bind-
ing assays were done with soluble I-A
g7 and I-A
k and
synthetic peptides. The IC50 value indicates the concentra-
tion of unlabeled peptide required to affect binding of a
reference peptide to the class II molecules: the higher the
value, the weaker the binding of the peptide to the MHC.
The PI-1(47–64) and PI-2(49–66) peptides bound poorly to
I-A
g7, with IC50 values of 98.9 and 135.9 mol/l, respec-
tively (Table 2). In contrast, these peptides bound more
strongly to I-A
k, with IC50 values of 4.8 and 2.1 mol/l,
respectively. The PI-1(49–61) peptide bound slightly bet-
ter to I-A
g7, with an IC50 of 20 mol/l, perhaps due to the
loss of the positively charged P62Lys, which is likely
disfavored at the carboxy-end of the peptide-binding
groove of I-A
g7. As a point of reference, the mouse
insulin-2 -chain (9–23) peptide bound to I-A
g7 with an
IC50 of 3 mol/l.
Reactivity to PI-1(47–64) is I-A
g7 dependent. The role
played by the MHC class II molecule, I-A
g7, and back-
ground genes in autoreactivity to C-peptide was examined
by characterizing the T-cell responses in NOD, NOD.h4,
B6.g7, and B10.BR mice. Mice were immunized with the
PI-1(47–64) peptide, and lymph nodes were examined on
day 7 by ELISPOT analysis for IL-2
 cells. Both I-A
g7–
containing strains, NOD and B6.g7, had peptide-reactive
T-cells (Fig. 1A and C), compared with the I-A
k strains
that did not (Fig. 1B and D). The frequency of PI-1(47–
64)–reactive cells detected under these conditions was
low: 1/30,000 in the NOD mice and 1/50,000 in the B6.g7
mice. However, PI-1(47–64)–speciﬁc T-cells were not de-
tected in the NOD.h4 and B10.BR mice. The T-cell reac-
tivity against PI-1(47–64) present in the NOD and B6.g7
mice was clearly I-A
g7 restricted as evidenced by inhibition
with MHC class II–blocking antibody, AG.2.42.7 (17).
These data demonstrate that I-A
g7 alone is necessary and
TABLE 1
Human and murine proinsulin sequences
1———————9—————————————23———-30
Human (b) FVNQHLCGSHLVEALYLVCGERGFFYTPKT
Mouse I FVKQHLCGPHLVEALYLVCGERGFFYTPKS
Mouse II FVNQHLCGSHLVEALYLVCGERGFFYTPMS
31————————————-47——49———————————61
Human (C) RREAEDLQVGQVELGGGPGAGSLQPLALEGSLQKR
Mouse I RREVEDPQVEQLELGGSP GDLQTLALEVARQKR
Mouse II RREVEDPQVAQLELGGGPGAGDLQTLALEVAQQKR
64————————————————-86
Human (a) GIVEQCCTSICSLYQLENYCN
Mouse I GIVDQCCTSICSLYQLENYCN
Mouse II GIVDQCCTSICSLYQLENYCN
The sequences of the human, mouse-1, and mouse-2 proinsulin
molecules are shown. The amino acid residues in bold are cleaved off
during the physiological processing of the prohormone, and C-
peptide is secreted in equimolar amount with the mature insulin
heterodimer. The amino acid residue numbering refers to the mouse
proinsulin-1 sequence, and the PI-1(47–64) segment is underlined.
TABLE 2
Binding to I-A
g7
Peptide Sequence
Binding
I-A
g7 I-A
k
MIME GKKVATTVHAGYG 1 —
PI-1(47–64) SPGDLQTLALEVARQKRG 98.9 4.8
PI-2(49–66) GAGDLQTLALEVAQQKRG 135.9 2.1
PI-1(49–61) GDLQTLALEVARQ 20.0 —
INS-B(9–23) SHLVEALYLVCGERG 3 —
This panel shows the binding analysis of synthetic peptides to
soluble I-A
g7 and I-A
k. Binding is expressed by IC50 values (mol/l).
The mime peptide is a synthetic reference peptide that has been used
in I-A
g7 binding assays (16). The binding of mouse insulin-2 B:(9–23)
(3 mol/l) peptide is presented as a point of reference. Binding
studies were performed at pH 5.5 as described in RESEARCH DESIGN AND
METHODS.
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pendent of other background genes.
PPLNs harbor C-peptide–reactive T-cells. Given the
central importance of the PPLNs in the priming of diabe-
togenic T-cells, we began by examining the PPLNs of
pre-diabetic mice for the presence of T-cells speciﬁc for
the PI-1(47–64) peptide. Like others (5,18), we did not
detect reactivity to proinsulin peptides in primary prolif-
eration assays with PPLNs or spleens from 10- to 16-week-
old NOD mice (data not shown). Given this difﬁculty in
detecting primary T-cell responses, we expanded PPLN
T-cells, in addition to T-cells from the spleen and periph-
eral lymph nodes, for 2 weeks in vitro with the PI-1(47–64)
peptide, and then tested all T-cells in the expanded cul-
tures for peptide reactivity. T-cells speciﬁc for the PI-1(47–
64) peptide were identiﬁed in the PPLNs from 10- to
16-week-old mice but were not found in the spleen or
axillary and inguinal lymph nodes (Fig. 2A and B). Five of
246 expanded T-cell lines from the PPLNs reacted with the
PI-1(47–64) peptide (stimulation index 5). In contrast,
no PI-1(47–64)–reactive T-cells were detected from the
454 T-cell lines expanded from the spleen or axillary and
inguinal lymph nodes. The presence of C-peptide–reactive
T-cells in the PPLNs was in agreement with previous data
that indicated these nodes as the site for priming of
diabetogenic T-cells (19–21). Moreover, this ﬁnding also
suggested a possible role for these T-cells in the early
pathogenesis of the disease. To further characterize the
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FIG. 1. The ACP T-cell repertoire in NOD mice is I-A
g7 dependent. Both I-A
g7–containing strains, NOD and B6.g7, had peptide-reactive T-cells (A
and C), compared with the I-A
k strains, NOD.h4 and B10.BR, that did not (B and D). The frequency of PI-1(47–64)–reactive cells detected under
these conditions was 1/30,000 in the NOD mice and 1/50,000 in the B6.g7 mice. However, PI-1(47–64)–speciﬁc T-cells were not detected in the
NOD.h4 and B10.BR mice. The T-cell response to PI-1(47–64) in NOD and B6.g7 mice was MHC class II restricted as evidenced by inhibition with
the MHC class II–blocking antibody, AG.2.42.7. Data presented are representative of three independent experiments.
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T-cell lines by immunization of young NOD mice.
NOD mice lack tolerance to the PI-1(47–64) self-
peptide. Mice were immunized with PI-1(47–64) peptide
in CFA, and several primary CD4
 T-cell lines were
generated, including the ACP 2 line (Fig. 3A). All lines
demonstrated similar reactivity in vitro; they were maxi-
mally stimulated by the PI(47–64) peptide from proinsu-
lin-1 and also reactive with the PI(49–66) peptide from
proinsulin-2. The T-cell lines also recognized the PI-1(49–
61) and the PI-2(51–63) segments, which differ only by one
residue (Arg for PI-1 at position 60 and Gln for PI-2 at
position 62). The T-cell lines were stimulated by the
full-length C-peptides from proinsulin 1 and 2, although
less than they were by the PI-1(47–64) peptide.
To determine whether the ACP T-cell lines were reactive
with the naturally processed and presented forms of the
proinsulin epitope, T-cells were tested for reactivity with
freshly isolated mouse -cells. All three primary ACP lines,
including ACP 2, reacted to dispersed mouse -cells from
young NOD mice (4–6 weeks of age) and -cells from
other strains such as 129/Svj (Fig. 3B). Furthermore, the
ACP T-cells reacted to dispersed islets isolated from
5-month-old NOD mice, demonstrating that APCs from the
islet inﬁltrate present the C-peptide epitope (Fig. 3C).
Minimal epitope mapping and antigen processing re-
quirements for C-peptide–reactive T-cells. Analysis of
ACP T-cell hybridomas showed heterogeneity in their
reactivity to truncated peptides (Fig. 4 A; Table 3). The
likely minimal T-cell epitope spanned the PI-1(51–61)
sequence (LQTLALEVARQ) because loss of the P51Leu
resulted in a noticeable decrease in T-cell activation for all
hybridomas examined (Fig. 4A; Table 3). Some T-cells,
such as ACP2.1, responded well to the PI-1(49–60) peptide
lacking the P61Gln, whereas others did not (see ACP1.28),
indicating variable requirements for carboxy-terminal res-
idues. Identiﬁcation of the nonamer canonical core within
the PI-1(51–61) segment could not be determined by T-cell
reactivity, and all T-cells tested (0 of 8) with the three
possible nonamers spanning the PI-1(51–61) peptide were
negative (51–59, LQTLALEVA; 52–60, QTLALEVAR; and
53–61, TLALEVARQ). These results may indicate a need
for amino- or carboxy-ﬂanking residues that serve as T-cell
receptor contacts, as was seen with the -chain (9–23)
epitope (2), loss of MHC binding afﬁnity with the truncated
peptides, or both.
To assess the requirements for antigen processing of the
C-peptide T-cell epitopes, T-cells were tested for reactivity
with synthetic peptides presented by ﬁxed APCs. We
found that ACP T-cell hybridomas were stimulated by
A
B
FIG. 2. PPLNs contain T-cells reactive with PI-1(47–64). A: T-cells from the PPLNs of NOD mice from 10–16 weeks of age contain
PI-1(47–64)–reactive T-cells. Five of 246 expanded T-cell lines from the PPLNs reacted with the SPGDLQTLALEVARQKRG peptide with a
stimulation index (SI) >5. In contrast, 0 of 454 T-cell lines expanded from the spleen or axillary and inguinal lymph nodes were stimulated by
the PI-1(47–64) peptide. B: Data from one representative experiment in which 41 T-cell lines from the PPLNs were tested for reactivity with the
PI-1(47–64) peptide.
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full-length C-peptide (Fig. 4B), indicating that all three
peptides, even the full-length C-peptide-1 29-mer, could
form recognizable complexes without the need for further
processing.
We next examined the stability of the peptide-MHC
complexes formed by PI-1(47–64) and I-A
g7 by functional
experiments in which T-cells were applied to antigen-
pulsed and washed APCs over an 8-h time course (Fig. 4C).
The antigen-pulsed APCs quickly lost their ability to
stimulate C-peptide–reactive T-cells. The T-cell response,
for both PI-1(47–64)– and C-peptide-1–pulsed APCs, was
reduced to 50% of its maximal value in 3 h, indicating that
the C-peptide–MHC complexes disassociated rapidly.
C-peptide–reactive T-cells induce diabetes. The patho-
genicity of the ACP primary T-cell lines was assessed by
adoptive transfer into NOD.scid recipient mice. Three
separate transfer experiments were performed: group 1
(n 	 8) received 9.4  10
6 ACP no. 1 T-cells; group 2 (n 	
4) received 17  10
6 ACP no. 2 T-cells; and group 3 (n 	
4) received three infusions of ACP nos. 1 and 2 T-cells. The
incidence of diabetes was 50% for all groups; group 1 (4
of 8) by 20 weeks after transfer, group 2 (2 of 4) at 10
and 20 weeks after transfer, and group 3 (2 of 4) at 20
and 22 weeks after transfer (Fig. 5A). The induction of
diabetes in 8/16 NOD.scid mice, which never naturally
develop diabetes, indicated that the ACP T-cells were
pathogenic in the adoptive transfer model. Although the
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FIG. 3. Primary anti–PI-1(47–64) T-cell lines are reac-
tive with -cells. A: Three primary anti–PI-1(47–64)
T-cell lines were generated by immunization of young
NOD mice. One such line, ACP no. 2, recognized the
PI-1(47–64) peptide in addition to the PI-1(49–61) seg-
ment and full-length C-peptide-1. The ACP no. 2 T-cell
line recognized peptides from the PI-2 sequence, al-
though not as well as PI-1. B: The ACP no. 2 T-cell line
responded to freshly isolated -cells from 4- to 6-week-
old NOD mice. In both peptide and -cell assays, irradi-
ated NOD splenocytes were used as APCs and cultures
were pulsed with labeled thymidine on day 2 and har-
vested on day 3. C: ACP no. 1 reacted to dispersed islets
from 5-month-old NOD mice in the absence of exogenous
APCs.
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less than some observed with activated T-cells from
T-cell receptor transgenic mice, e.g., BDC2.5 the inci-
dence is similar to the spontaneous incidence seen in
wild-type NOD mice. Furthermore, all recipient mice,
including those that were not overtly hyperglycemic at
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FIG. 4. ACP T-cells respond to PI-1(49–61), and full-length C-peptide presented by ﬁxed APCs and the peptide-MHC (pMHC) complexes
disassociate rapidly. A: The ACP1.28 T-cell responds well to PI-1(49–61):GDLQTLALEVARQ; however, reactivity was abolished with the loss of
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GDLQTLALEVAR rather well and responded weakly to both PI-1(52–61):QTLALEVARQ and PI-1(49–59):GDLQTLALEVA. B: Both ACP1.28 and
ACP2.1 responded strongly to ﬁxed APCs pulsed with peptide, indicating that further processing of the peptide was not required. This was true
for the PI-1(47–64) and PI-1(49–61) epitopes and the full-length C-peptide-1 molecule (peptide concentration 30 mol/l; experiments performed
in triplicate). C: The stability of the pMHC complexes formed from PI-1(47–64) or C-peptide-1 was examined by adding T-cells to antigen-pulsed
and washed APCs over an 8-h time course. The percent maximal response was determined by dividing the T-cell response at T4 or T8, in counts
per minute by the value achieved when the T-cells were added at T0. APCs pulsed with either PI-1(47–64) or C-peptide-1 lost 50% of their ability
to maximally stimulate T-cells in 3 h, indicating that the pMHC complexes disassociated rapidly on the surface of the APCs.
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DISCUSSION
The main ﬁndings from these studies are 1) binding of the
PI-1(47–64) and PI-1(49–61) peptides to I-A
g7 is incredibly
poor, and the peptide-MHC complexes are short-lived; 2)
I-A
g7 plays a central role in the generation of the ACP
T-cell repertoire, in that autoreactivity was found to
strains bearing I-A
g7 but not I-A
k molecules; 3) C-peptide–
reactive T-cells are found in the PPLNs of pre-diabetic
NOD mice; 4) ACP T-cells are reactive with mouse -cells
and respond to full-length C-peptide presented by live and
ﬁxed APCs; and 5) despite this weak peptide-MHC inter-
action, C-peptide–reactive T-cells are capable of causing
diabetes in an adoptive transfer model.
Our data conﬁrm and extend the observations of other
groups that have identiﬁed the C-peptide region of proin-
sulin as a CD4
 T-cell target in the NOD mouse
(5,13,22,23). The recovery of C-peptide–reactive T-cells
from the PPLNs and not from other locations suggests that
these T-cells may encounter their antigen in this critically
important site of diabetogenic T-cell priming (19–21,24).
Intra-islet APCs, most likely dendritic cells, must encoun-
ter large amounts of C-peptide in the islets and may trafﬁc
to the PPLNs, where they could prime and activate naı ¨ve
C-peptide–reactive T-cells. Alternatively, lymphatic drain-
age of the pancreas might deliver high concentrations of
C-peptide to the PPLNs, allowing uptake and presentation
by nodal dwelling APCs. The islets readily provided anti-
gen to APCs (Fig. 3B), and APCs recovered from insulitic
islets stimulated the T-cells (Fig. 3C). In either case, it is
not difﬁcult to imagine a scenario in which PPLNs are
exposed to large amounts of C-peptide, which would be
required for activation of the T-cells by these very weak
MHC-binding peptides. Although C-peptide circulates, its
concentration in blood (2–5 nmol/l) would not be sufﬁcient
for either activation or regulation in APCs at peripheral
sites.
Why are C-peptide–reactive T-cells not deleted in the
thymus? Weak MHC-binding peptides may well be the
best at fostering autoimmunity, in great part by avoiding
negative selection in the thymus or by failure of regula-
tory mechanisms, although other factors are likely to
play a role. The PI-1(47–64) epitope represents a strik-
ing example of a very poor binding MHC ligand, IC50
values 100 mol/l, that gives rise to T-cells capable of
causing diabetes in adoptive transfer experiments. The
relationship between poor peptide-MHC binding and the
fostering of an autoimmune, pathogenic T-cell reper-
toire has been suggested in studies on experimental
allergic encephalomyelitis (7,8) and in our recent work
on the insulin -chain (9–23) epitope (2) and in other
model systems (9–11).
The obligatory role for the diabetogenic I-A
g7 mole-
cule in eliciting C-peptide–reactive CD4 T-cells remains
a key issue. Our results with the four mouse strains
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FIG. 5. ACP T-cells transferred disease into recipient NOD.scid mice
and caused severe insulitis. A: Adoptive transfer of ACP T-cells into
NOD.scid recipient mice induced diabetes in 50% (8 of 16) by 22 weeks
after transfer. See RESEARCH DESIGN AND METHODS for details. B: Histology
of islets from all recipient mice, diabetic and normoglycemic, showed
severe, destructive insulitis. The islet histology shown in this ﬁgure
was taken from a nondiabetic recipient mouse at 30 weeks after
transfer.
TABLE 3
ACP T-cell half-maximal stimulatory concentration values
1.23 1.24 1.28 1.56 2.1 2.55 2.78 2.87
SPGDLQTLALEVARQKRG 0.3 0.13 0.06 0.25 0.1 0.025 0.03 0.07
GDLQTLALEVARQ — 30 0.9 3.5 2 1.2 1.5 6
DLQTLALEVARQ — 30 4 6 2.5 1.6 2.5 6
LQTLALEVARQ — 30 4 15 3 2.1 5 6
QTLALEVARQ ———— 30 30 30 30
GDLQTLALEVAR — — 30 15 2 — — —
GDLQTLALEVA ———— 30 — — —
GDLQTLALEVAQQ — — — 0.6 0.5 — — —
Values shown are concentrations of peptide required to half-maximally stimulate a given T-cell (mol/l; —, none detected). Values are
averages of two to ﬁve independent experiments.
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g7), NOD.h4 (I-A
k), B6.g7 (I-A
g7), and
B10.BR (I-A
k) demonstrated that expression of I-A
g7,
independent of the genetic background, was sufﬁcient
to generate C-peptide–reactive CD4 T-cells (Fig. 1). This
is in agreement with previous data from Kanagawa et al.
(25) and Ridgway et al. (26), indicating that the expres-
sion of I-A
g7 in different strains of mice allowed escape
of autoreactive T-cells. A more recent study from Strat-
mann et al. (27) used MHC tetramers to trace islet-
reactive CD4
 T-cells in I-A
g7–expressing mice of
different genetic backgrounds. Here again, the expres-
sion of I-A
g7 in different strains selected for tetramer-
reactive CD4
 T-cells. The NOD strain has also been
shown to be susceptible to other autoimmune diseases
(28–31). Taken together, these data point to a central
role for I-A
g7 in selection (or escape) of autoreactive
T-cells. We believe that the explanation lies in the
structural features of I-A
g7, characterized by an overall
low peptide-binding afﬁnity and instability (32), in addi-
tion to other susceptibility genes. These ﬁndings do not
lessen the importance of other factors in NOD mice that
play a role in the loss of self tolerance (33–35). The fact
that B6.g7 mice do not develop diabetes highlights the
need of both MHC- and non-MHC–encoded susceptibil-
ity genes.
A second important factor in the lack of T-cell tolerance
may be speciﬁc to the insulin molecule. It may be that the
peptide-MHC complexes formed in the thymus do not
recapitulate the complexes that appear in the periphery.
The deleting complexes are presumably formed by the
traditional processing and presentation of proinsulin pep-
tides in thymic medullary epithelial cells. Here, peptides
are selected by the biological and physical forces that
govern peptide presentation by I-A
g7 molecules in thymic
cells and are not the same as events that might occur in the
periphery. Although proinsulin is clearly expressed in the
thymus (36,37), perhaps largely under the control of the
autoimmune regulator transcription factor (38), there is no
evidence of the expression of the prohormone processing
machinery, such as the prohormone convertases 1 and 2,
which would be required to generate the actual C-peptide
fragment that is secreted by the -cell. The absence of
tolerance to C-peptide, as it is presented in the pancreas,
may be explained, in a sense, by the lack of a secretory
apparatus in the thymus.
The data presented here extend our understanding of
the role of proinsulin as an autoantigen and again seem to
illustrate an inverse relationship between weak peptide-
MHC binding and T-cell autoimmune pathogenicity. The
degree to which C-peptide–reactive T-cells contribute to
disease pathogenesis in the NOD mouse cannot be deter-
mined with certainty. The T-cells were pathogenic in
circumstances of adoptive transfer, and they represent
one set of the many proinsulin-reactive T-cells that seem
to play a key role in the development of autoimmune
diabetes. The identiﬁcation of T-cell reactivity against
C-peptide epitopes in type 1 diabetic patients suggests that
C-peptide might also be an important autoantigen in the
human disease (39–42).
ACKNOWLEDGMENTS
This work was supported by grants from the Barnes-
Jewish Hospital Foundation, the National Institutes of
Health (DK-067199 and DK-020279), and the Kilo Diabetes
and Vascular Research Foundation.
We thank Shirley Petzold for technical assistance.
REFERENCES
1. Suri A, Levisetti MG, Unanue ER: Do the peptide-binding properties of
diabetogenic class II molecules explain autoreactivity? Curr Opin Immu-
nol 20:105–110, 2008
2. Levisetti MG, Suri A, Petzold SJ, Unanue ER: The insulin-speciﬁc T cells of
nonobese diabetic mice recognize a weak MHC-binding segment in more
than one form. J Immunol 178:6051–6057, 2007
3. Daniel D, Gill RG, Schloot N, Wegmann D: Epitope speciﬁcity, cytokine
production proﬁle and diabetogenic activity of insulin-speciﬁc T cell
clones isolated from NOD mice. Eur J Immunol 25:1056–1062, 1995
4. Abiru N, Wegmann D, Kawasaki E, Gottlieb P, Simone E, Eisenbarth GS:
Dual overlapping peptides recognized by insulin peptide B:9–23 T cell
receptor AV13S3 T cell clones of the NOD mouse. J Autoimmun 14:231–
237, 2000
5. Halbout P, Briand JP, Becourt C, Muller S, Boitard C: T cell response to
preproinsulin I and II in the nonobese diabetic mouse. J Immunol
169:2436–2443, 2002
6. Nakayama M, Abiru N, Moriyama H, Babaya N, Liu E, Miao D, Yu L,
Wegmann DR, Hutton JC, Elliott JF, Eisenbarth GS: Prime role for an
insulin epitope in the development of type 1 diabetes in NOD mice. Nature
435:220–223, 2005
7. Fairchild PJ, Wildgoose R, Atherton E, Webb S, Wraith DC: An autoanti-
genic T cell epitope forms unstable complexes with class II MHC: a novel
route for escape from tolerance induction. Int Immunol 5:1151–1158, 1993
8. Liu GY, Fairchild PJ, Smith RM, Prowle JR, Kioussis D, Wraith DC: Low
avidity recognition of self-antigen by T cells permits escape from central
tolerance. Immunity 3:407–415, 1995
9. McNeil LK, Evavold BD: Dissociation of peripheral T cell responses from
thymocyte negative selection by weak agonists supports a spare receptor
model of T cell activation. Proc Natl Acad SciUSA99:4520–4525, 2002
10. Gross DA, Graff-Dubois S, Opolon P, Cornet S, Alves P, Bennaceur-
Griscelli A, Faure O, Guillaume P, Firat H, Chouaib S, Lemonnier FA,
Davoust J, Miconnet I, Vonderheide RH, Kosmatopoulos K: High vaccina-
tion efﬁciency of low-afﬁnity epitopes in antitumor immunotherapy. J Clin
Invest 113:425–433, 2004
11. Geluk A, van Meijgaarden KE, Schloot NC, Drijfhout JW, Ottenhoff TH,
Roep BO: HLA-DR binding analysis of peptides from islet antigens in
IDDM. Diabetes 47:1594–1601, 1998
12. Rubenstein AH, Clark JL, Melani F, Steiner DF: Secretion of proinsulin
C-peptide by pancreatic beta cells and its circulation in blood. Nature
224:697–699, 1969
13. Jaeckel E, Lipes MA, von Boehmer H: Recessive tolerance to preproinsulin
2 reduces but does not abolish type 1 diabetes. Nat Immunol 5:1028–1035,
2004
14. Kappler JW, Skidmore B, White J, Marrack P: Antigen-inducible, H-2-
restricted, interleukin-2-producing T cell hybridomas: lack of independent
antigen and H-2 recognition. J Exp Med 153:1198–1214, 1981
15. Lacy PE, Kostianovsky M: Method for the isolation of intact islets of
Langerhans from the rat pancreas. Diabetes 16:35–39, 1967
16. Latek RR, Suri A, Petzold SJ, Nelson CA, Kanagawa O, Unanue ER,
Fremont DH: Structural basis of peptide binding and presentation by the
type I diabetes-associated MHC class II molecule of NOD mice. Immunity
12:699–710, 2000
17. Suri A, Vidavsky I, van der Drift K, Kanagawa O, Gross ML, Unanue ER: In
APCs, the autologous peptides selected by the diabetogenic I-Ag7 mole-
cule are unique and determined by the amino acid changes in the P9
pocket. J Immunol 168:1235–1243, 2002
18. Hurtenbach U, Maurer C: Type I diabetes in NOD mice is not associated
with insulin-speciﬁc, autoreactive T cells. J Autoimmun 2:151–161, 1989
19. Hoglund P, Mintern J, Waltzinger C, Heath W, Benoist C, Mathis D:
Initiation of autoimmune diabetes by developmentally regulated presenta-
tion of islet cell antigens in the pancreatic lymph nodes. J Exp Med
189:331–339, 1999
20. Gagnerault MC, Luan JJ, Lotton C, Lepault F: Pancreatic lymph nodes are
required for priming of beta cell reactive T cells in NOD mice. J Exp Med
196:369–377, 2002
21. Levisetti MG, Suri A, Frederick K, Unanue ER: Absence of lymph nodes in
NOD mice treated with lymphotoxin-beta receptor immunoglobulin pro-
tects from diabetes. Diabetes 53:3115–3119, 2004
22. Chen W, Bergerot I, Elliott JF, Harrison LC, Abiru N, Eisenbarth GS,
Delovitch TL: Evidence that a peptide spanning the B-C junction of
proinsulin is an early Autoantigen epitope in the pathogenesis of type 1
diabetes. J Immunol 167:4926–4935, 2001
23. Martinez NR, Augstein P, Moustakas AK, Papadopoulos GK, Gregori S,
M.G. LEVISETTI AND ASSOCIATES
DIABETES, VOL. 57, JULY 2008 1859Adorini L, Jackson DC, Harrison LC: Disabling an integral CTL epitope
allows suppression of autoimmune diabetes by intranasal proinsulin
peptide. J Clin Invest 111:1365–1371, 2003
24. Sarukhan A, Lechner O, von Boehmer H: Autoimmune insulitis and
diabetes in the absence of antigen-speciﬁc contact between T cells and
islet beta-cells. Eur J Immunol 29:3410–3416, 1999
25. Kanagawa O, Martin SM, Vaupel BA, Carrasco-Marin E, Unanue ER:
Autoreactivity of T cells from nonobese diabetic mice: an I-Ag7-dependent
reaction. Proc Natl Acad SciUSA95:1721–1724, 1998
26. Ridgway WM, Ito H, Fasso M, Yu C, Fathman CG: Analysis of the role of
variation of major histocompatibility complex class II expression on
nonobese diabetic (NOD) peripheral T cell response. J Exp Med 188:2267–
2275, 1998
27. Stratmann T, Martin-Orozco N, Mallet-Designe V, Poirot L, McGavern D,
Losyev G, Dobbs CM, Oldstone MB, Yoshida K, Kikutani H, Mathis D,
Benoist C, Haskins K, Teyton L: Susceptible MHC alleles, not background
genes, select an autoimmune T cell reactivity. J Clin Invest 112:902–914,
2003
28. Goillot E, Mutin M, Touraine JL: Sialadenitis in nonobese diabetic mice:
transfer into syngeneic healthy neonates by splenic T lymphocytes. Clin
Immunol Immunopathol 59:462–473, 1991
29. Many MC, Maniratunga S, Denef JF: The non-obese diabetic (NOD) mouse:
an animal model for autoimmune thyroiditis. Exp Clin Endocrinol Diabe-
tes 104 (Suppl. 3):17–20, 1996
30. Salomon B, Rhee L, Bour-Jordan H, Hsin H, Montag A, Soliven B, Arcella
J, Girvin AM, Padilla J, Miller SD, Bluestone JA: Development of sponta-
neous autoimmune peripheral polyneuropathy in B7–2-deﬁcient NOD
mice. J Exp Med 194:677–684, 2001
31. Beales PE, Castri F, Valiant A, Rosignoli G, Buckley L, Pozzilli P:
Adrenalitis in the non-obese diabetic mouse. Autoimmunity 35:329–333,
2002
32. Carrasco-Marin E, Shimizu J, Kanagawa O, Unanue ER: The class II MHC
I-Ag7 molecules from non-obese diabetic mice are poor peptide binders.
J Immunol 156:450–458, 1996
33. Kishimoto H, Sprent J: A defect in central tolerance in NOD mice. Nat
Immunol 2:1025–1031, 2001
34. Lesage S, Hartley SB, Akkaraju S, Wilson J, Townsend M, Goodnow CC:
Failure to censor forbidden clones of CD4 T cells in autoimmune diabetes.
J Exp Med 196:1175–1188, 2002
35. Zucchelli S, Holler P, Yamagata T, Roy M, Benoist C, Mathis D: Defective
central tolerance induction in NOD mice: genomics and genetics. Immu-
nity 22:385–396, 2005
36. Jolicoeur C, Hanahan D, Smith KM: T-cell tolerance toward a transgenic
beta-cell antigen and transcription of endogenous pancreatic genes in
thymus. Proc Natl Acad SciUSA91:6707–6711, 1994
37. Chentouﬁ AA, Polychronakos C: Insulin expression levels in the thymus
modulate insulin-speciﬁc autoreactive T-cell tolerance: the mechanism by
which the IDDM2 locus may predispose to diabetes. Diabetes 51:1383–
1390, 2002
38. Anderson MS, Venanzi ES, Klein L, Chen Z, Berzins SP, Turley SJ, von
Boehmer H, Bronson R, Dierich A, Benoist C, Mathis D: Projection of an
immunological self shadow within the thymus by the aire protein. Science
298:1395–1401, 2002
39. Semana G, Gausling R, Jackson RA, Haﬂer DA: T cell autoreactivity to
proinsulin epitopes in diabetic patients and healthy subjects. J Autoim-
mun 12:259–267, 1999
40. Durinovic-Bello I, Boehm BO, Ziegler AG: Predominantly recognized
proinsulin T helper cell epitopes in individuals with and without islet cell
autoimmunity. J Autoimmun 18:55–66, 2002
41. Arif S, Tree TI, Astill TP, Tremble JM, Bishop AJ, Dayan CM, Roep BO,
Peakman M: Autoreactive T cell responses show proinﬂammatory polar-
ization in diabetes but a regulatory phenotype in health. J Clin Invest
113:451–463, 2004
42. Toma A, Haddouk S, Briand JP, Camoin L, Gahery H, Connan F, Dubois-
Laforgue D, Caillat-Zucman S, Guillet JG, Carel JC, Muller S, Choppin J,
Boitard C: Recognition of a subregion of human proinsulin by class
I-restricted T cells in type 1 diabetic patients. Proc Natl Acad SciUSA
102:10581–10586, 2005
C-PEPTIDE–REACTIVE T-CELLS
1860 DIABETES, VOL. 57, JULY 2008